AngioDynamics Inc ANGO.OQ ANGO.O is expected to show a rise in quarterly revenue when it reports results on July 15 for the period ending May 31 2025
The Latham New York-based company is expected to report a 4.6% increase in revenue to $74.256 million from $70.98 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for AngioDynamics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 40.8% above its last closing price of $9.48
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Feb. 28 2025
-0.14
-0.13
0.03
Beat
123.1
Nov. 30 2025
-0.10
-0.11
-0.04
Beat
63.6
Aug. 31 2024
-0.15
-0.15
-0.11
Beat
25
May. 31 2024
-0.16
-0.17
-0.06
Beat
64
Feb. 29 2024
-0.13
-0.14
-0.16
Missed
-18.3
Nov. 30 2023
-0.09
-0.07
-0.05
Beat
33.3
Aug. 31 2023
-0.13
-0.13
-0.12
Beat
7.7
May. 31 2023
0.03
0.02
0.02
Met
-11.1
This summary was machine generated July 11 at 12:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)